• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Shared decision-making in atrial fibrillation: navigating complex issues in partnership with the patient
AbstractAtrial fibrillation (AF) is an important risk factor for stroke. Although anticoagulation is effective in mitigating this risk, many high-risk patients are not anticoagulated in routine practice. Furthermore, as many as 50% of those who are prescribed an anticoagulant stop treatment within a year. This under treatment may be due, in part, to difficulty in navigating difficult decisions about initiating potentially lifelong therapy with significant costs, potential risks, and impact on daily life. To address these challenges, the most recent American guidelines issued a class I recommendation to use shared decision-...
Source: Journal of Interventional Cardiac Electrophysiology - October 17, 2018 Category: Cardiology Source Type: research

Stroke treatment, outcomes improve at hospitals participating in UCLA-led initiative
Administering a clot-dissolving drug to stroke victims quickly — ideally within the first 60 minutes after they arrive at a hospital emergency room — is crucial to saving their lives, preserving their brain function and reducing disability. Given intravenously, tPA (tissue plasminogen activator) is currently the only Food and Drug Administration–approved therapy shown to improve outcomes for patients suffering acute ischemic stroke, which affects some 800,000 Americans annually. Now, a UCLA-led study demonstrates that hospitals participating in the "Target: Stroke" national quality-improvement program have markedly...
Source: UCLA Newsroom: Health Sciences - April 23, 2014 Category: Universities & Medical Training Source Type: news

Timely treatment after stroke is crucial, UCLA researchers report
For years, the mantra of neurologists treating stroke victims has been "time equals brain." That's because getting a patient to the emergency room quickly to receive a drug that dissolves the stroke-causing blood clot can make a significant difference in how much brain tissue is saved or lost.   But specific information has been limited on just how the timing of giving the intravenous drug — known as a tissue plasminogen activator, or tPA — influences outcomes for victims of ischemic (clot-caused), stroke, the most common type of stroke.   Now, a team led by UCLA researchers has conducted a major stud...
Source: UCLA Newsroom: Health Sciences - June 18, 2013 Category: Universities & Medical Training Source Type: news

Novel Oral Anticoagulants and Gastrointestinal Bleeding: a Case for Cardiogastroenterology
With the rapidly evolving cardiology drug pipeline for treatment of acute coronary syndrome (ACS), gastroenterologists have witnessed the emergence of a new population of patients who are vulnerable to gastrointestinal (GI) bleeding: the chronic cardiac patient. ACS, causing myocardial infarction (MI) and unstable angina, and atrial fibrillation are the signature conditions of the chronic cardiac patient. The morbidity and mortality of ACS is significant. Chronic cardiac patients are prescribed complex antithrombotic therapy (CAT) (ie, aspirin [ASA] plus a thienopyridine, eg, clopidogrel [Plavix; Bristol-Myers Squibb/Sanof...
Source: Clinical Gastroenterology and Hepatology - January 23, 2013 Category: Gastroenterology Authors: Neena S. Abraham Tags: Comment From the Editor Source Type: research